Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3 AUD | -1.64% | -7.69% | +46.34% |
Mar. 12 | Dimerix Raises AU$20 Million for Kidney Disease Study | MT |
Mar. 11 | Dimerix Expanding Kidney Drug Study After DMX-200 Performs Better than Placebo | MT |
Sales 2022 | 6.47M 4.21M | Sales 2023 | 8.98M 5.85M | Capitalization | 24.06M 15.68M |
---|---|---|---|---|---|
Net income 2022 | -10M -6.52M | Net income 2023 | -13M -8.47M | EV / Sales 2022 | 4.48 x |
Net cash position 2022 | 9.56M 6.23M | Net cash position 2023 | 2.03M 1.33M | EV / Sales 2023 | 2.45 x |
P/E ratio 2022 |
-3.37
x | P/E ratio 2023 |
-1.46
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 67.92% |
1 day | -1.64% | ||
1 week | -7.69% | ||
Current month | +33.33% | ||
1 month | +42.86% | ||
3 months | +42.86% | ||
6 months | +376.19% | ||
Current year | +46.34% |
Managers | Title | Age | Since |
---|---|---|---|
Nina Webster
CEO | Chief Executive Officer | - | 18-08-26 |
Hamish George
DFI | Director of Finance/CFO | - | 19-05-05 |
David Fuller
CTO | Chief Tech/Sci/R&D Officer | - | 23-10-22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Nina Webster
CEO | Chief Executive Officer | - | 18-08-26 |
Hugh Alsop
BRD | Director/Board Member | - | 17-04-30 |
Mark Diamond
CHM | Chairman | - | 23-01-11 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 0.3 | -1.64% | 2 683 913 |
24-03-27 | 0.305 | +3.39% | 4,322,774 |
24-03-26 | 0.295 | -1.67% | 4,031,983 |
24-03-25 | 0.3 | -6.25% | 6,132,192 |
24-03-22 | 0.32 | -5.88% | 3,700,270 |
Delayed Quote Australian S.E., March 28, 2024 at 01:10 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
+46.34% | 109M | |
+9.43% | 45.97B | |
+52.73% | 43.93B | |
+7.29% | 42.34B | |
-8.78% | 28.27B | |
+18.48% | 27.18B | |
-21.26% | 19.44B | |
+14.79% | 13.83B | |
+32.71% | 12.4B | |
+5.05% | 11.45B |